Cardiovascular Events, Hematopoietic Stem Cell Transplantation, Transplant Complication
Conditions
Brief summary
This is a prospective, multicenter observational study for recipients of hematopoietic stem cell transplantation. Patients who underwent hematopoietic stem cell transplantation at the participating centers will be entrolled in the study. The clinical characteristics, laboratory profiles, management measures, and clinical outcomes such as post-transplant cardiovascular events will be prospectively collected.
Interventions
None listed
Sponsors
Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences)
First Affiliated Hospital of Zhejiang University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Xinqiao hospital of the third military medical university
The First Affiliated Hospital of Zhengzhou University
Sun Yat-sen University Cancer Center, Sun Yat-sen University
Sichuan Provincial People's Hospital
First Affiliated Hospital of Harbin Medical University
First Affiliated Hospital Xi'an Jiaotong University
First Affiliated Hospital of Xinjiang Medical University
Chinese PLA General Hospital
Peking University Shenzhen Hospital
Peking University Third Hospital
Peking University First Hospital
Peking University People's Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients who undergo hematopoietic cell transplantation at any of the participating medical centers.
Exclusion criteria
* Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data. * Patient request to withdraw from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major adverse cardiovascular events (MACE) | At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation. | Major adverse cardiovascular events (MACE) after hematopoietic stem cell transplantation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiovascular events | At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation. | Cardiovascular events after hematopoietic stem cell transplantation, such as cardiovascular death, ischemic heart disease, coronary artery disease, stroke, heart failure, arrhythmia cardiomyopathy, myocarditis, endocarditis, valvular heart disease, and pericardial disease. |
| Overall survival | At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation. | Overall survival after hematopoietic stem cell transplantation. |
| Event-free survival | At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation. | Events were defined as the occurrence of any of the following after allo-HSCT: grade III-IV acute graft-versus-host disease (GVHD), chronic GVHD requiring systemic immunosuppression, relapse or progression of the hematologic disease, or death from any cause during follow-up. |
| Complications of hematopoietic stem cell transplantation | At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation. | Complications arising from hematopoietic stem cell transplantation range from early issues such as regimen toxicity and acute GVHD to late effects including chronic GVHD, organ dysfunction, and secondary malignancies. |
Countries
China
Contacts
Primary ContactXiao Hui Zhang
Outcome results
None listed